BioCryst Pharmaceuticals Inc (BCRX) FY2025Q4 Earning Prediction
BioCryst Pharmaceuticals Inc (BCRX) is set to release its earnings performance on 02/25 05:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 150.00M and an earnings per share (EPS) of 0.06 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Earnings Surprise Analysis
BCRX Transcript
The earnings call summary indicates strong financial performance, with a significant increase in ORLADEYO revenue and improved profitability. Despite some uncertainties in the preclinical programs, management's optimistic guidance and strategy for pediatric HAE approval, coupled with a robust financial position post-European business sale, suggest a positive outlook. The market cap indicates a small-cap stock, which typically reacts more strongly, supporting a positive prediction.
BCRX Slides
BCRX Report
Frequently Asked Questions
What is the BioCryst Pharmaceuticals Inc FY2025Q4 Earnings Release Date and Time?
BioCryst Pharmaceuticals Inc (BCRX) is scheduled to release its FY2025Q4 earnings report onFeb 25, 2026, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for BioCryst Pharmaceuticals Inc FY2025Q4 Revenue and EPS?
Analysts' consensus predicts 150.00M in revenue and an EPS of 0.00 for BioCryst Pharmaceuticals Inc's FY2025Q4.
What Does Intellectia's AI Predict for BioCryst Pharmaceuticals Inc FY2025Q4 Earnings?
Intellectia's exclusive AI algorithms forecast a forBioCryst Pharmaceuticals Inc's FY2025Q4 earnings, with a prediction date of Feb 25, 2026. BioCryst Pharmaceuticals Inc
How Can I Use This Earnings Prediction to Trade BCRX Stock?
Leverage Intellectia's AI forecast to position trades ahead of theFeb 25, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like BioCryst Pharmaceuticals Inc FY2025Q4?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
